Skip to main content
TipRanks
Go Ultimate75% OFF

Gabather AB (GABA) AI Stock Analysis

0 Followers
SE:GABA

Gabather AB

(Nasdaq OMX AB:GABA)

Select Model
Rating:40Underperform
Price Target:SEK 0.02â–¼(-5.56% Downside)
Action:reiterated
Date:11/11/26

Gabather AB's overall score of 40 is heavily weighed down by its pre-revenue status, significant cash burn, and absolute reliance on external capital. Although a pristine, debt-free balance sheet provides essential structural safety for an early-stage biotech, the stock is heavily pressured by a deeply negative valuation profile and a strong technical downtrend across all major moving averages.

Positive Factors
Debt-Free Balance SheetThe absence of reported debt limits interest obligations and reduces direct leverage pressure while the company advances its pipeline. Although financial resources remain constrained, a debt-free structure provides greater flexibility than a heavily leveraged balance sheet if future funding is secured.
Negative Factors
No Revenue TractionThe absence of revenue means Gabather has not yet demonstrated commercial demand or an operating model capable of funding its activities. Continued reliance on development progress before sales begin leaves the company exposed to a long path from research investment to recurring business income.

Gabather AB (GABA) vs. iShares MSCI Sweden ETF (EWD)

-50%-25%0%25%50%75%100%125%SE:GABA-37.93%EWD+15.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 10.99M
Dividend Yield
―
Average Volume (3M)
2.41M
Price to Earnings (P/E)
-1.1
Beta (1Y)
0.73
Revenue Growth
―
EPS Growth
65.27%
Country
Sweden
Employees
2
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Gabather AB Business Overview & Revenue Model

Company Description

Gabather AB (publ) is dedicated to creating innovative pharmaceutical solutions for a range of central nervous system disorders. The company's focus includes developing medications for conditions such as psychotic illnesses, mood and anxiety disorder...

Gabather AB Financial Statement Overview

Summary

Gabather AB is a pre-revenue clinical drug manufacturer facing persistent net losses and significant cash burn. While the balance sheet benefits from a completely debt-free profile, the company lacks internal funding capabilities and relies entirely on external equity financing to sustain operations.

Income Statement

15Very Negative

Balance Sheet

45Neutral

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit000000
EBITDA-4.90M-4.53M037.00K3,000-16.91M
Net Income-5.00M-4.65M-7.75M-9.44M-8.54M-17.00M
Balance Sheet
Total Assets4.54M3.83M1.83M7.36M6.75M15.39M
Cash, Cash Equivalents and Short-Term Investments3.69M3.14M878.00K1.11M6.27M14.85M
Total Debt000000
Total Liabilities3.08M4.69M6.01M6.88M3.31M4.43M
Stockholders Equity1.46M-863.00K-4.17M486.00K3.44M10.96M
Cash Flow
Free Cash Flow-7.13M-7.22M-3.33M-11.64M-9.60M-16.12M
Operating Cash Flow-7.13M-7.22M-3.33M-11.64M-9.60M-16.12M
Investing Cash Flow000000
Financing Cash Flow7.82M9.49M3.09M6.49M1.02M46.00K

Gabather AB Technical Analysis

Technical Analysis SentimentNegative
Last Price0.02

Price Trends

50DMA0.02Negative
100DMA0.03Negative
200DMA0.03Negative

Market Momentum

MACD-0.00Negative
RSI39.18Neutral
STOCH33.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GABA, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 39.18 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:GABA.

Gabather AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:GABA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CAMXSE:CAMX78OutperformSEK 44.18B57.4416.50%―2.96%-4.07%
SE:SANIONSE:SANION77OutperformSEK 1.63B8.8029.71%―24.98%-31.44%
SE:BIOA.BSE:BIOA.B65NeutralSEK 27.05B256.135.18%0.70%-46.09%-90.13%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ALZCURSE:ALZCUR49NeutralSEK 852.21M10.30105.09%―――
SE:ORXSE:ORX42NeutralSEK 315.79M-0.08-115.03%―-97.68%-83.26%
SE:GABASE:GABA40UnderperformSEK 10.99M-1.08-2479.40%――65.27%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%SE:GABASE:CAMXSE:ORXSE:ALZCURSE:BIOA.BSE:SANIONDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:GABA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:GABAGabather AB0.02-0.01-37.93%
SE:CAMXCamurus AB729.50109.0017.57%
SE:ORXOrexo AB0.90-16.07-94.70%
SE:ALZCURAlzeCure Pharma AB6.184.41249.35%
SE:BIOA.BBioArctic AB Class B304.8023.878.50%
SE:SANIONSaniona AB11.79-5.39-31.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026